Section 35.394 - Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries)Except as provided in § 35.57 , the licensee shall require an authorized user for the oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 Gigabecquerels (33 millicuries), to be a physician who-
(a) Is certified by a medical specialty board whose certification process includes all of the requirements in paragraphs (c)(1) and (2) of this section, and whose certification has been recognized by the Commission or an Agreement State. The names of board certifications that have been recognized by the Commission or an Agreement State are posted on the NRC's Medical Uses Licensee Toolkit web page; or(b) Is an authorized user under § 35.390 for uses listed in § 35.390(b)(1)(ii)(G) (2) or equivalent Agreement State requirements; or(c)(1) Has successfully completed 80 hours of classroom and laboratory training, applicable to the medical use of sodium iodide I-131 for procedures requiring a written directive. The training must include-(i) Radiation physics and instrumentation;(ii) Radiation protection;(iii) Mathematics pertaining to the use and measurement of radioactivity;(iv) Chemistry of byproduct material for medical use; and(v) Radiation biology; and(2) Has work experience, under the supervision of an authorized user who meets the requirements in §§ 35.57 , 35.390 , 35.394 , or equivalent Agreement State requirements. A supervising authorized user, who meets the requirements in § 35.390(b) , must also have experience in administering dosages as specified in § 35.390(b)(1)(ii)(G)(2) . The work experience must involve-(i) Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys;(ii) Performing quality control procedures on instruments used to determine the activity of dosages and performing checks for proper operation of survey meters;(iii) Calculating, measuring, and safely preparing patient or human research subject dosages;(iv) Using administrative controls to prevent a medical event involving the use of byproduct material;(v) Using procedures to contain spilled byproduct material safely and using proper decontamination procedures; and(vi) Administering dosages to patients or human research subjects, that includes at least 3 cases involving the oral administration of greater than 1.22 gigabecquerels (33 millicuries) of sodium iodide I-131; and(3) Has obtained written attestation that the individual has satisfactorily completed the requirements in paragraphs (c)(1) and (2) of this section, and is able to independently fulfill the radiation safety-related duties as an authorized user for oral administration of greater than 1.22 gigabecquerels (33 millicuries) of sodium iodide I-131 for medical uses authorized under § 35.300 . The attestation must be obtained from either:(i) A preceptor authorized user who meets the requirements in § 35.57 , § 35.390 , § 35.394 , or equivalent Agreement State requirements, and has experience in administering dosages as specified in § 35.390(b)(1)(ii)(G) (2); or(ii) A residency program director who affirms in writing that the attestation represents the consensus of the residency program faculty where at least one faculty member is an authorized user who meets the requirements in § 35.57 , § 35.390 , § 35.394 , or equivalent Agreement State requirements, has experience in administering dosages as specified in § 35.390(b)(1)(ii)(G) (2), and concurs with the attestation provided by the residency program director. The residency training program must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Council on Postdoctoral Training of the American Osteopathic Association and must include training and experience specified in paragraphs (c)(1) and (2) of this section.67 FR 20370, Apr. 24, 2002, as amended at 68 FR 75389, Dec. 31, 2003; 70 FR 16365, Mar. 30, 2005; 71 FR 15010, Mar. 27, 2006; 74 FR 33905, July 14, 2009; 83 FR 33108, July 16, 2018